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Objectives. To identify possible mechanisms for destruction of valves in chronic venous hypertension and the results of
treatment with an anti-inflammatory micronized purified flavonoid fraction.
Material and methods. The saphenous vein valves in a rat model of venous hypertension caused by a femoral arterial-
venous fistula were studied. Studies included femoral venous pressure, valve morphology, femoral venous reflux and selected
molecular inflammatory markers as examined by immunohistochemistry. The effects of treatment with the anti-
inflammatory micronized purified flavonoid fraction (S 5628, Servier, 50 and 100 mg/kg/day) were investigated.
Results. The femoral venous pressure was elevated close to arterial values for a period of 3 weeks. We then examined the
morphology of the veins and selected molecular inflammatory markers were assessed.
The results show that in this model venous reflux develops in response to venous hyptertension. This can be inhibited by the
administration of the anti-inflammatory micronized purified flavonoid fraction (S 5628, Servier, 50 and 100 mg/kg/day).
The valve becomes incompetent by a combination of venous dilation and shortening of the valve leaflets. This is not inhibited
by treatment with S 5628.
The valve leaflets are infiltrated with granulocytes, monocytes and T-lymphocytes, and the endothelial cells express enhanced
levels of P-selectin and ICAM-1. Cells in the valves are subject to extensive apoptosis although no enhancement of MMP 2,9
expression could be detected at the three-week time point examined in this study.
Conclusions. These results indicate that in this model chronic elevation of venous pressure is associated with an
inflammatory reaction in venous valves, a process that may lead to their dysfunction, reflux, and upstream elevation of
venous pressure. These effects are mitigated by the anti-inflammatory micronized purified flavonoid fraction in a dose
dependent manner.
Key Words: Arterio-venous fistula; Valve reflux; Apoptosis; Granulocytes; Monocytes; Macrophages; Lymphocyte;
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Introduction
Clinical evidence shows that chronic venous insuffi-
ciency is linked to venous hypertension, which is the
result of valve failure and venous reflux.1 There are
two major mechanisms that cause venous hyperten-
sion in the lower extremities of man. The first is due to
the weight of the blood column from the right atrium
transmitted through the valveless vena cava and iliac
veins to the femoral vein and sapheno-femoral
junction in the upper thigh. The second is due to
venous blood pressure generated by contracting
skeletal muscles in the lower extremity transmitted
through failed valves in perforating veins.2
When valve failure occurs in superficial and
perforating veins, the pressure in the veins and
venules of the skin and subcutaneous tissues is raised
and flow can be reversed.3 Such an abnormal
haemodynamic flow pattern may lead to restructuring
in the superficial veins and venules, which are
mechanically less well supported than deep veins.
Angioscopic observations during varicose vein sur-
gery have revealed marked alterations in incompetent
saphenous veins.4 Changes, which have been seen,
include valve cusp perforation, tearing, elongation of
cusps and valve disappearance.5,6
In examining surgical specimens from limbs with
chronic venous insufficiency, we found that leucocytes
and membrane adhesion molecules were more numer-
ous on proximal surfaces of venous valves and vein
walls than on distal venous regions of the valves.7
Chronic venous reflux is associated with significantly
increased leucocyte–endothelial cell interactions and
an increased number of activated leucocytes.8 Since
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25% of vein valves were severely damaged and non-
functional, a link between venous hypertension above
the valve and damage to the valve structure was
postulated. Surgical specimens are inevitably removed
during late, chronic stages after many years of venous
insufficiency. Mechanisms that cause venous valve
destruction during acute phases of primary venous
insufficiency cannot readily be studied in man and
they remain currently unknown. Yet these phenomena
may be accompanied by endothelial cell activation and
enhancement of proinflammatory gene product levels,
which in turn may be associated with venous wall
injury.
Venous hypertension is associated with highly
unsteady pressure values. Distal veins are subjected
to pressure peaks generated by contracting muscles,
which in normal limbs may reach values in excess of
150 mmHg.9 Proximal veins are also subject to
pressure peaks generated by intra-abdominal strain-
ing, obesity and abdominal wall pressure.10 We
hypothesize that during acute venous pressure
elevation there is a shift of the venous haemodynamics
with changes in wall shear stress. Unsteady shear
stresses and venous distension may cause polymor-
phonuclear cell (PMN) and monocyte/macrophage
and endothelial cell activation so that leucocytes
become attached to the endothelium of the vein wall
and valve leaflets. As a consequence, apoptosis and/or
necrosis may occur in the endothelium, smooth
muscle cells, fibroblasts as well as parenchymal cells
of the venous wall. In addition, activated inflamma-
tory and endothelial cells may degrade extracellular
matrix components such as elastin, collagen, laminin
and fibronectin by release of oxygen free radicals and
proteolytic matrix metalloproteinases (MMPs).11 The
venous valve leaflets and wall structures may be
weakened and ultimately destroyed, thus producing
the gross changes clinically observed. This sequence of
events may trigger primary venous insufficiency and
explain the apparent deficiency of valves with venous
dysfunction.12
Following the hypothesis that venous hypertension
is linked to valve damage and subsequent valve
failure, we examined in this study key elements of
this hypothesis in an experimental model of venous
hypertension caused by creation of an arterio-venous
fistula (AVF) between the femoral vessels of the Wistar
rat.13 We made measurements vein morphological
parameters related to venous insufficiency and key
inflammatory mediators. We also examined the effects
of an anti-inflammatory micronized purified flavonoid
fraction (S 5628, Servier, Paris, France) in regard to
venous endothelial damage and leucocyte mediated




The animal procedures in this study were reviewed
and approved by the Animal Subjects Committee of
the University of California San Diego. Male Wistar
rats (250–300 g, Charles River Laboratory, Inc., Wil-
mington, MA, n ¼ 18) were operated on under general
anaesthesia (pentobarbital sodium, 50 mg/kg, i.m.)
without tracheotomy in order to allow the animals to
breathe spontaneously.
Arterio-venous fistula
A femoral AVF was created unilaterally in the groin
using sterile microsurgical techniques as described by
van Bemmelen.13 Fig. 1 shows the relevant structures
in the groin of the Wistar rat.
Mono-filament sutures (9–0 to 12–0, Ethicon) were
used to create a 0.5 mm fistula between the femoral
artery and vein proximal to the sapheno-femoral
junction. To avoid cardiac failure after placement of
the shunt (AVF), tributaries to the femoral vein
including the superficial epigastric vein near the
anastomosis were ligated. To prevent blood coagu-
lation, heparin was administered (1000 U/kg B.W.).
The skin incision was closed and the rats were given
intense postsurgical care. The rats were housed in a
light-cycle controlled flow hood and maintained on
Fig. 1. Diagram of the femoral artery and vein and adjacent
anatomy. The arterio-venous fistula was created unilaterally
in the right groin using sterile microsurgical techniques
(modified from Ref. 25 with permission).
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standard pellet diet and water ad libitum. The rats
with the AVF were maintained for a period of 3 weeks.
This time period was selected following a series of
pilot studies (see Section 3), which showed significant
dysfunction in the first valve distal to the fistula. The
fistula generated a blood pressure on the first distal
femoral vein valve within about 90% of the femoral
arterial pressure.
Treatment groups
Vehicle (5% gum Arabic in distilled water) and the
micronized purified flavonoid fraction (MPFF) S 5628
(50 and 100 mg/kg/day body weight, Servier, Paris,
France, P.O.) was administrated daily using an animal
feeding tube (16 £ 3 in. size with 3 mm diameter ball;
Popper and Sons, Inc., New York, NY). Treatment was
started 4 days prior to placement of the AVF and
continued until completion of the study. S4582 was
prepared in the vehicle at concentration of 10 and
20 mg/ml. Each animal received 0.5 ml of vehicle or S
5682 suspension per 100 g body weight.
Valve reflux and morphology
At the end of the treatment period, the animals were
anaesthetised (pentobarbital sodium, 50 mg/kg, i.m.).
The femoral vein was sectioned distal to its proximal
valve. Reflux through the valve was determined for
each rat by timed collection of the backflow in the
presence of the native femoral pressure (see Section 3).
The femoral vein was dissected and opened long-
itudinally to permit examination of the valve leaflet
structure and shape. The following morphological
measures were obtained: length of vein half circle,
valve height, leaflet height, valve sinus length, edge
length and leaflet width (Fig. 2).
Leucocyte infiltration and membrane adhesion molecule
expression
Valve specimens were immediately frozen in liquid
nitrogen and stored at 270 8C until examination.
Longitudinal sections of 6 mm thickness were cut
across the valve leaflets with a cryostat at 2238, air
dried for 30 min, and then fixed in purified acetone for
9 min as described in detail elsewhere.14 Leucocyte
infiltration, expression of endothelial adhesion mol-
ecules, metalloproteinase (MMP) and apoptotic mar-
kers were labelled on the frozen sections with
appropriate antibodies. These included anti-bodies
against macrophages (monoclonal Ab HIS36), T-
lymphocytes (OX-52), granulocytes (HIS 48), ICAM-1
(1A29), the nuclear transcription factor IkBa (SC-371),
NFkB proteins p50 (SC-8414) p65 (SC 109), the MMPs
MMP-2 (42-SD11) and MMP-9 (SC6840), and terminal
deoxynucleotidyl transferase mediated dUTP nick end
labeling (TUNEL, Trevigen kit TACS 2). Secondary
biotinylated antibodies were applied with peroxidase-
conjugated avidin to yield a dark brown reaction
product, as previously described.14
The sections were examined with light microscopy
at several magnifications up to 100 £ objective
(numerical aperture 1.4). In addition to direct micro-
scopic observations, the expression of molecular
markers was determined by direct light absorption
measurements after image digitisation on a laboratory
computer (Power Mac, Macintosh Computer) and
expressed in terms of optical density units.
Intravital microscopy of the gracilis muscle
microcirculation
The microcirculation distal to the pressurized femoral
vein and superficial postcapillary venules in the
gracilis muscle were examined by intravital
microscopy as described previously.15 Briefly, red cell
and white cell velocities were measured with the dual
slit method (mm/s). The number of leucocytes in
postcapillary venules adherent to the endothelium
(per unit vessel length) and the number of leucocyte
migrating across the endothelium (per vessel length)
were counted from intravital records using video
record replay. Between 4 and 7 venules per rat with
diameters between 25 and 90 mm were examined.
Statistics
All values were expressed as means and SD. Differ-
ences between the treatment groups were analysed by
repeated measure analysis of variance combined with
Fig. 2. Schematic diagram of geometric parameters
measured to assess venous valve structure. Note that venous
valves are bi-leaflets. The diagram illustrates an enface view
of one leaflet after longitudinal sectioning of the vein into
two equal halves.
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a Scheffe-type multiple comparison test. Mann–
Whitney’s U Tests were performed for comparison
between the 0 and 100 mg/kg/day S 5682 treatment
groups. A value of P , 0:05 was considered signifi-
cant. The analysis was performed on Statview (Version
4.5 for Macintosh, Abacus Concepts Inc. Berkeley, CA).
Results
Immediately after opening the AVF, the distal femoral
vein and saphenous vein were distended and pulsatile
flow could be seen passing through the fistula through
the wall of the veins.
The pressure in the femoral veins was significantly
increased from 11 S.D. 2 mmHg to 94 S.D. 9 mmHg
mean pressure immediately after creating the AVF
while mean systemic pressure was relatively
unchanged (92 S.D. 4 mmHg in controls versus 97
S.D. 8 mmHg ðn ¼ 3Þ in animals with AVF.
Reflux across the saphenous vein valve
To determine the time interval required to produce
significant reflux across the saphenous valves, veins
distal to the AVF were tested for reflux at 2 days (n ¼ 3
rats), 1 week ðn ¼ 4Þ; 2 weeks ðn ¼ 4Þ and 3 weeks ðn ¼
4Þ after fistula placement. At 2 days, the dependent
saphenous veins were dilated but no reflux was
detected. At 1 week, one of four veins exhibited reflux.
At 2 weeks, two veins showed reflux and all others
were patent without reflux. At 3 weeks, three of four
veins showed reflux. In all rats the valves in the
contralateral femoral and saphenous vein segments
were patent. Therefore, for the treatment component
of this study, a three-week time interval was selected.
Timed reflux volume was measured in all speci-
mens ex vivo. The reflux volume in veins with AVF was
greatly enhanced. But there was no difference in the
incidence of reflux between the treatment groups
(Table 1).
MPFF significantly reduced the reflux rate in a
dose-dependent manner (Fig. 3). These results suggest
that MPFF delays the development of the reflux in this
model.
Valve morphology
There were significant differences between control
(without fistula) veins and veins with AVF in the
length of 1/2 circle circumference around the vein. The
pressure produced by the AVF caused about a 25%
dilation of the veins (Fig. 4(A)). MPFF did not prevent
the dilation of the veins (Fig. 4(A)). Leaflet height was
significantly reduced by the presence of the fistula,
which was not prevented by pretreatment with MPFF
(Fig. 4(B)).
The fistula caused a reduced leaflet width. Pretreat-
ment with MPFF (100 mg/kg for 3 weeks) decreased
this shortening significantly (Fig. 4(C)). The valve
height was reduced in the presence of the fistula, and
this was significantly attenuated by treatment with
MPFF (Fig. 4(D)). Neither MPFF treated nor untreated
experimental groups exhibited significant differences
in valve edge length between control and AVF
exposed veins. However, creation of the AVF tended
to elongate the edge length (n.s.) (Fig. 4(E)). There
were no differences in the sinus length between control
veins and the veins exposed to the AVF in any
treatment group (Fig. 4(F)).
Leucocyte infiltration
We identified granulocytes in all regions of the vein
wall. The number of granulocytes infiltrating into the
vein wall was enhanced by the presence of the A-V
fistula (Fig. 5(A)). We recognised a trend for MPFF to
attenuate this infiltration but average leucocyte counts
Fig. 3. Reflux flow rates across the saphenous venous valve
measured after 3 weeks of venous hypertension in vehicle
control and MPFF treatment groups at a dose of 50 and
100 mg/kg/d. n is the number of rats in each group.
†P , 0:05 (Mann–Whitney U test) compared to the control.
Table 1. Incidence of vein valve reflux after A-V fistula placement
Treatment Number of veins Number of cases with reflux (incidence %)
AVF 12 8 (67)
AVF þMPFF (50 mg/kg) 8 7 (88)
AVF þMPFF (100 mg/kg) 11 7 (64)
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Fig. 4.Morphological measurements of venous valves as defined in Fig. 2. The black bars represent the contralateral controls
without venous hypertension; the light bars represent the groups with venous hypertension due to presence of the AVF. n is
the number of rats in each group. *P , 0:05 compared to treatment (Scheffe), †P , 0:05 compared to the control (Mann–
Whitney U test).
S. Takase et al.488
Eur J Vasc Endovasc Surg Vol 28, November 2004
on the histological sections were not significantly
different. The average number of monocyte/macro-
phages infiltrating the tissue was enhanced in all
groups with fistula but there was no statistically
significant difference between treatment and control
groups (Fig. 5(B)). The number of T-lymphocytes in the
venous wall was significantly enhanced in the veins
with a fistula (Fig. 6(A)) a trend, which could be
attenuated with MPFF treatment. No such effect was
observed in the case of B-lymphocytes (Fig. 6(B)).
Endothelial cell adhesion molecule expression
The expression of P-selectin and ICAM-1 on the
endothelial cells of the saphenous vein wall was
increased in the AVF groups.MPFF tended to suppress
their enhancement (Fig. 7(A) and (B)).
Matrix metalloproteinases (MMPs)
We could not detect a significant enhancement of
MMP-2 or MMP-9 expression in the veins with fistula
compared with non-fistula controls (Fig. 8). The
expression of MMP-2 in the AVF group with 50 mg/
kg/d of MPFF was enhanced (Fig. 8(A)). The
expression of MMP-9 in the group with fistula and
pretreated with 50 and 100 mg/kg/d MPFF also
seemed to be enhanced (Fig. 8(B)).
NFkB expression
In the NFkB family, IkBa was not increased in any of
Fig. 5. The number of (A) granulocytes and (B) monocy-
tes/macrophages per tissue crossectional area infiltrating
venous valve leaflets ðP , 0:05Þ (Mann–Whitney U test).
Control refers to normotensive control valves, AVF is the
vehicle control for the MPFF treatment groups at a dose of 50
and 100 mg/kg/d. The control group are contralateral
valves not exposed to pressure elevation. n is the number
of rats in each group.
Fig. 6. The number of T and B-lymphocytes per vessel cross-
sectional area in the saphenous venous valve leaflets. For
description of groups see Fig. 5.
Fig. 7. The level of (A) P-selectin and (B) ICAM-1 expression
on the endothelial cells on the saphenous venous valve
leaflets. Groups are the same as in Fig. 5. *P , 0:05 (Mann–
Whitney U test) compared with control.
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the experimental groups (Fig. 9(A)). The expression of
p50 was increased in the AVF group pretreated with
MPFF 50 mg/kg/d but was decreased after treatment
with 100 mg/kg/d MPFF. The expression of p65 was
enhanced in veins with fistula during treatment with
100 mg/kg/d MPFF (Fig. 9(B)).
Apoptotic cells
The number of TUNEL-positive cells in the vein wall
was increased in the AVF group, and pretreatment
with MPFF tended (n.s.) to attenuate the number of
apoptotic cells in a dose-dependent manner (Fig. 10).
Leucocyte infiltration into the gracilis muscle
microcirculation
Surgery for placement of the AVF required clamping
of the femoral artery and vein but was completed
within 20 min. After reperfusion of the femoral artery
and vein, leucocytes adhered to the endothelium of the
postcapillary venules in the gracilis muscle micro-
circulation in the AVF groups (Fig. 11). MPFF
pretreatment for 3 days significantly decreased the
number of adherent leucocytes toward control levels
in a dose-dependent manner.
The number of leucocytes migrating across the
postcapillary venular wall gradually increased in the
group with AVF. In the control group, fewer migrating
leucocytes were detected. MPFF significantly reduced
the leucocyte migration at the 60 min observation time
point after surgery (Fig. 11).
The velocity of the red blood cells and white blood
cells exhibited no significant shift in average values
between the groups (Fig. 12(A) and (B)).
Discussion
The observations in the rat suggest that acute venous
hypertension in the femoral vein, induced by an AV
fistula, is accompanied by significant distension of the
structures of adjacent valves. At 3 weeks of hyperten-
sion valvular function is compromised in this model
due to dilation of the venous wall and the valve ring to
the point of incomplete valve closure and subsequent
reflux. We could detect by microscopy only mild tissue
damage in the valve leaflets as compared to an intact
valve without pressure elevation. Associated with the
distension of the venous wall and valve annulus
dilation is the development of inflammatory indicators.
We could detect markers of inflammation in form of
T-cell, granulocyte and macrophage infiltration into
Fig. 8. The level of (A) MMP-2 and (B) MMP-9 expression in
the saphenous venous valves after 3 week of venous
hypertension. Groups are the same as in Fig. 5. *P , 0:05
compared normotensive control. †P , 0:05 (Mann–Whitney
U test) compared to the control.
Fig. 9. The level of the transcription factor NFkB markers (A)
IkBa, (B) p50, and (C) p65 expressions in the saphenous
venous valves after 3 week of venous hypertension due to
AVF. Groups are the same as in Fig. 5.
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the vein wall and an increased expression of endo-
thelial membrane adhesion molecules (P-selectin,
ICAM-1). The situation is not unlike valve failure in
the heart16 and in venous insufficiency in man.7
In contrast, we could detect at 3 weeks no
significant enhancement of metalloprotease levels
(MMP-2, 9), or nuclear transcription factor (NFkB)
levels using the histological techniques. While there
may be several explanations for this behaviour, the
lack of expression may partially be due to an
enhanced apoptosis in the venous valves which are
exposed to hypertension, so that MMP-2, 9 or NFkB
levels may only be expressed temporarily in
individual cells prior to apoptosis. The more rapid
the apoptosis progresses in the tissue the lower the
probability of detecting markers for inflammation
with histological techniques. The issue requires
further investigations at other time points of venous
pressure elevation.
The current model represents a severe form of
venous pressure elevation, so that stress induced
inflammation and apoptosis may be enhanced above
levels encountered in man with less severe pressure
elevations. Dilation of the venous wall interferes with
the ability of the venous leaflets to close properly and
prevent reflux. The ability of the leaflets to close the
venous lumen is further compromised by the fact that
the leaflet dimensions (height and width, Fig. 4(B) and
(C)) are reduced and the edges may even become
corrugated, a feature not seen in controls but seen in
chronic valve incompetence in man.17 We did not
Fig. 10. The level of cell TUNEL labeling in the leaflets of the
saphenous valve. Groups are the same as in Fig. 5. *P , 0:05
compared to normotensive control (Scheffe).
Fig. 11. The number of leucocytes (A) adhering to the
endothelium of postcapillary venules in the gracilis muscle
microcirculation and (B) migrating into the adjacent post-
capillary venules within an hour after production of venous
hypertension by placement of an AVF. Groups are the same
as explained in the legend of Fig. 5. *P , 0:05 compared to
control. †P , 0:05 compared to the treatment. (Mann–
Whitney U test).
Fig. 12. (A) White blood cell velocity and (B) red blood cell
velocity measured with intravital techniques in postcapillary
venules of the gracilis muscle microcirculation. Mean and
standard deviation is shown for each group. The number of
measurements in each rat is about 4–7 capillary venules.
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encounter in the current model fenestrations in the
venous leaflets as reported in man.18
What sequence of events may lead to the morpho-
logical abnormalities in venous valves? Direct obser-
vation of the veins immediately after placement of the
AV fistula shows a large expansion of the venous wall
under the elevated pressure although the leaflets are
still able to close properly in the early stages of the
AVF. At this stage there is no reduction of the valve
length or width. Thus the pressure per se is not
necessarily the variable that may compromise the
leaflets. In contrast, at the time the leaflets fail and
reflux occurs, we see a reduction of the leaflet
dimensions. This indicates that as the venous wall
dilates and a point may be reached at which reflux
develops across the leaflets. Then destruction of the
leaflets may be induced by an abnormal fluid shear
field produced at the surface of the leaflets during
venous reflux. Such a fluid shear stress-mediated
process, if accompanied by unsteady shear stress or
even turbulence, can be highly inflammatory for the
endothelial cells on the valve leaflets and may trigger
apoptosis and mechanical softening of the leaflet and
the venous wall.19–22
Leucocyte infiltration into the venous leaflets is one
of the hallmarks of the inflammatory process. Such an
event is confirmed in the current study and is in line
with our previous histological observations in the
valves7 and venous wall of patients with venous
dysfunction.23,24 Additional signs of inflammation are
encountered in the acute phase of venous pressure
elevation.15,25,26
The micronized purified flavonoid fraction (S 5682,
Daflonw 500 mg), consisting of 90% diosmin and 10%
hesperidin, reduced reflux through veins, which were
subjected to profound venous hypertension. S 5682 has
been shown to reduce leucocyte interaction with the
endothelium in acute venous hypertension and
inflammation15,26–30 and is used clinically to treat
chronic venous insufficiency. In the current chronic
model, several indicators of the ensuing inflammatory
reaction (adhesion molecule expression, leucocyte
infiltration) were reduced. These and the level of
apoptosis were influenced in a dose dependent
fashion. While not all of the observed trends were
statistically significant, they did reveal the ability of
MPFF to suppress damage to the valve structures. The
previously published observations of an anti-inflam-
matory effect of MPFF under acute situations may
have a protective effect on the venous valves in chronic
conditions in our venous hypertension model.
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